AMAG Pharmaceuticals — Q1 2020 Earnings Presentation
14 slides from AMAG Pharmaceuticals's earnings presentation, May 11, 2020
Slide 1: AMAG Pharmaceuticals First Quarter 2020 Financial Results
AMAG Pharmaceuticals First Quarter 2020 Financial Results May 11, 2020 © 2020 AMAG Pharmaceuticals, Inc. All rights reserved 1
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including, among others, expectations
Slide 3: Agenda
1 Introduction of AMAG's New CEO 2 Managing Through COVID‐19 and Beyond AGENDA 3 Commercial Update 4 Financial Results 5 2020 Goals / Q&A © 2020 AMAG Pharmaceuticals, Inc. All rights reserved 3
Slide 4: Scott Myers: AMAG President and Chief Executive Officer
Scott Myers: AMAG President and Chief Executive Officer • Most recently served as Chairman and CEO of Rainier Therapeutics, a clinical‐stage biotechnology company focused on metastatic bladder cancer • Previously served as CEO, President and as a director of Cascadian Therapeutics Inc. (CASC) – Tuky
Slide 5: Executing the Strategy in a COVID-19 Environment
Executing the Strategy in a COVID-19 Environment In the process of right-sizing Continued focus on the organization for the future HemOnc and Maternal Health Restructured organization to reflect the planned Strong markets still exist divestiture of Intrarosa® and Vyleesi® for Feraheme® and Makena® a
Slide 6: Commercial Update: Core Value Drivers Feraheme and Makena
Commercial Update Core Value Drivers: Feraheme and Makena FIRST QUARTER REVENUE Feraheme Makena $44.4 $40.0 $31.3 • Q1‐2020 revenue growth of • Q1‐2020 revenue of $21.8M was +11% over Q1‐2019 $21.8 $3.8M below Q4‐2019 revenue • Average market share of 17.2% in • Average market share of 62% in Q1‐202
Slide 7: First Quarter Financial Results
First Quarter Financial Results1 $M Q1-2020 Q1-2019 Feraheme $44.4 $40.0 • Revenues Makena 21.8 31.3 – Feraheme revenue up 11% over Q1‐2019 Intrarosa 3.2 4.4 – Makena revenue stable post FDA Advisory Committee Other (0.7) 0.1 meeting in Q4‐2019 Total revenues $68.7 $75.8 • Operating Costs and Expens
Slide 8: Withdrawing 2020 Financial Guidance
Withdrawing 2020 Financial Guidance • COVID‐19 is adversely impacting patient access to AMAG’s products Previously Issued Financial Guidance – Patient visits have declined significantly in recent weeks ($M) 2020 Financial Guidance – Impact on products could continue into 2H‐2020 Total revenue $230 ‐
Slide 9: AMAG Remains Committed to Our Customers and Their Patients
AMAG Remains Committed to Our Customers and Their Patients Products Remain Available; Clinical Trials Impacted All products Supply chain at this time has • Continue to closely monitor suppliers and supply levels currently remain not been materially affected • Risk mitigation plans in place to minimi
Slide 10: 2020 Goals
2020 Goals GOAL STATUS Complete successful CEO transition Complete Divest Intrarosa and Vyleesi to align with new strategic direction Negotiations ongoing; update planned by the end of Q2‐2020 Drive continued Feraheme growth Sales and Medical Affairs teams engaged during COVID‐19 pandemic Maintain p
Slide 11: Q&A
AMAG Pharmaceuticals Q&A © 2019 AMAG Pharmaceuticals, Inc. All© rights 2020 reservedAMAG Pharmaceuticals, Inc. All rights reserved 11
Slide 12: Appendix
Appendix 12
Slide 13: Reconciliation of GAAP to Non-GAAP Preliminary Financial Results
Reconciliation of GAAP to Non-GAAP Preliminary Financial Results ($M) Q1-2020 Q1-2019 GAAP operating loss ($19.6) ($117.7) Depreciation and intangible asset amortization 10.3 4.4 Stock‐based compensation 3.8 4.2 Restructuring ‐‐ 7.4 Acquired IPR&D ‐‐ 74.9 Acquisition‐related costs ‐‐ 0.2 Non-GAAP ad
Slide 14: AMAG Pharmaceuticals First Quarter 2020 Financial Results
AMAG Pharmaceuticals First Quarter 2020 Financial Results May 11, 2020 © 2019 AMAG Pharmaceuticals, Inc. All© rights 2020 reservedAMAG Pharmaceuticals, Inc. All rights reserved 14